ARGX Argenx SE stock chart & analysis
Conviction 56HealthcareScan · Fri, Nov 6, 2026Argenx SE (ARGX) closed at $927.21 (+3.63%) on Nov 6, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 56, RS Rating 79, -13.5% from its 52-week high, +10.4% year to date. Sector: Healthcare · Biotechnology.
ARGX technical analysis
Trend
ARGX's moving averages are mixed — no clean uptrend or downtrend. It closed 0.3% below the 50-day ($930.69) and 8.3% above the 200-day ($857.05). ADX(14) at 18 points to a weak trend — more range than direction. It meets 7 of 8 trend-template criteria.
Momentum
RSI(14) is 56, in the bullish half of its range. The MACD histogram is positive. Its RS Rating of 79 puts its weighted 12-month performance ahead of about 79% of the US market.
Volume and volatility
Volume on the latest session ran 0.8× its 20-day average. It trades about $362.2M a day on average. ATR(14) is $30.57, 3.3% of price — its typical daily range. Chaikin Money Flow (0.07) shows accumulation.
Key levels
The chart pattern's support is $793.11 and its resistance $990.42. The 52-week range is $661.85 to $1,072.75; price is 13.5% below the high and 40.3% above the low. The VWAP anchored at the 52-week high is $899.22, below price.
Performance
ARGX returned +4.0% (1 week), +13.4% (1 month), +7.2% (3 months), +18.7% (6 months), +11.5% (1 year), +10.4% (year to date).
About Argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Biotechnology · Listed 2017 · 1,863 employees
Congress activity
Disclosed STOCK Act trades in ARGX · 1 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Alan Armstrong senate · R · OK · traded 2026-03-30 | Buy | $1K–$15K | 2026-03-30 | 2026-07-21 |
SEC filings
EDGAR filings in ARGX · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.